CoChat

Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review

Open access
Iervolino, Matteo, Lepore, Elisa, Forte, Gianpiero, Laganà, Antonio Simone, Buzzaccarini, Giovanni, Unfer, Vittorio · 2021 · Nutrients
Cited by 98

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Polycystic ovary syndrome (PCOS) is a heterogenous disorder characterized by chronic ovulation dysfunction and hyperandrogenism. It is considered the most common endocrinological disorder, affecting up to 25% of women of reproductive age, and associated with long-term metabolic abnormalities predisposing to cardiovascular risk, such as insulin resistance (IR), dyslipidemia, endothelial dysfunction, and systemic inflammation. PCOS is also characterized by elevated serum levels of luteinizing hormone (LH), causing a condition of hyperandrogenism and a consequent altered ratio between LH and the follicle stimulating hormone (FSH). Over the years, several different approaches have been proposed to alleviate PCOS symptoms. Supplementation with natural molecules such as inositols, resveratrol, flavonoids and flavones, vitamin C, vitamin E and vitamin D, and omega-3 fatty acids may contribute to overcoming PCOS pathological features, including the presence of immature oocyte, IR, hyperandrogenism, oxidative stress and inflammation. This review provides a comprehensive overview of the current knowledge about the efficacy of natural molecule supplementation in the management of PCOS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu13051677

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 86

  1. Papaleo, 2007, Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction, Gynecol. Endocrinol., 23, 700, 10.1080/09513590701672405 · DOI · Paper page
  2. Barnard, 2007, Quality of life and psychological wellbeing in polycystic ovary syndrome, Hum. Reprod., 22, 2279, 10.1093/humrep/dem108 · DOI · Paper page
  3. Dunaif, 1997, Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis, Endocr. Rev., 18, 774
  4. Vauhkonen, 2000, Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome, Hum. Reprod., 15, 1266, 10.1093/humrep/15.6.1266 · DOI · Paper page
  5. Alexandraki, 2006, Inflammatory and endothelial markers in women with polycystic ovary syndrome, Eur. J. Clin. Investig., 36, 691, 10.1111/j.1365-2362.2006.01712.x · DOI · Paper page
  6. ESHRE, The Rotterdam, and ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod., 19, 41–47. · DOI · Paper page
  7. McLuskie, 2017, New diagnosis of polycystic ovary syndrome, BMJ, 12, 356:i6456
  8. Welt, 2006, Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: The impact of weight on phenotype and metabolic features, J. Clin. Endocrinol. Metab., 91, 4842, 10.1210/jc.2006-1327 · DOI · Paper page
  9. Pehlivanov, 2007, Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population, Gynecol. Endocrinol., 23, 604, 10.1080/09513590701536246 · DOI · Paper page
  10. Glinicki, 2012, Phenotype and metabolic disorders in polycystic ovary syndrome, ISRN Endocrinol., 2012, 569862
  11. Kar, 2013, Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: A prospective study of PCOS women, J. Hum. Reprod. Sci., 6, 194, 10.4103/0974-1208.121422 · DOI · Paper page
  12. Jamil, 2015, A case–control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria, Reprod. Health, 12, 7, 10.1186/1742-4755-12-7 · DOI · Paper page
  13. Nestler, 1997, Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications, Semin. Reprod. Endocrinol., 15, 111, 10.1055/s-2007-1016294 · DOI · Paper page
  14. Baillargeon, 2003, Insulin sensitizers for polycystic ovary syndrome, Clin. Obstet. Gynecol., 46, 325, 10.1097/00003081-200306000-00011 · DOI · Paper page
  15. Mayer, 2015, Polycystic ovary syndrome and insulin: Our understanding in the past, present and future, Womens Health, 11, 137
  16. Ciampelli, 1999, Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome, Metabolism, 48, 167, 10.1016/S0026-0495(99)90028-8 · DOI
  17. Genazzani, 2004, Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome, Fertil. Steril., 81, 114, 10.1016/j.fertnstert.2003.05.020 · DOI
  18. Holte, 1994, The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women, Clin. Endocrinol., 41, 473, 10.1111/j.1365-2265.1994.tb02578.x · DOI · Paper page
  19. Robinson, 1996, Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries, Clin. Endocrinol., 44, 277, 10.1046/j.1365-2265.1996.674495.x · DOI · Paper page
  20. Venkatesan, 2001, Insulin resistance in polycystic ovary syndrome: Progress and paradoxes, Recent Prog. Horm. Res., 56, 295, 10.1210/rp.56.1.295 · DOI · Paper page
  21. Dunaif, 2006, Insulin resistance in women with polycystic ovary syndrome, Fertil. Steril., 86, S13, 10.1016/j.fertnstert.2006.04.011 · DOI
  22. Jakimiuk, 2014, The role of inositol deficiency in the etiology of Polycystic ovary syndrome disorders, Ginekol. Pol., 85, 54, 10.17772/gp/1691 · DOI
  23. Daughaday, 1955, The synthesis of inositol in the immature rat ANC chick embryo, J. Biol. Chem., 212, 869, 10.1016/S0021-9258(18)71025-9 · DOI
  24. Garzon, 2018, Inositol in polycystic ovary syndrome: Restoring fertility through a pathophysiology-based approach, Trends Endocrinol. Metab., 29, 768, 10.1016/j.tem.2018.09.001 · DOI · Paper page
  25. Unfer, 2017, Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials, Endocr. Connect., 6, 647, 10.1530/EC-17-0243 · DOI · Paper page
  26. Monastra, 2018, Alpha-lactalbumin effect on myo-inositol intestinal absorption: In vivo and in vitro, Curr. Drug Deliv., 15, 1305, 10.2174/1567201815666180509102641 · DOI · Paper page
  27. Bevilacqua, 2015, Results from the international consensus conference on myo-inositol and d-chiro-inositol in obstetrics and gynecology-assisted reproduction technology, Gynecol. Endocrinol., 31, 441, 10.3109/09513590.2015.1006616 · DOI · Paper page
  28. Colazingari, 2013, The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: Results froma randomized controlled trial, Arch. Gynecol. Obstet., 288, 1405, 10.1007/s00404-013-2855-3 · DOI
  29. Ravanos, 2017, Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality?, Eur. Rev. Med. Pharmacol. Sci., 21, 5491
  30. Dinicola, 2014, The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome, J. Clin. Pharmacol., 54, 1079, 10.1002/jcph.362 · DOI · Paper page
  31. Bevilacqua, 2019, Myo-inositol and D-Chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model, J. Cell. Physiol., 234, 9387, 10.1002/jcp.27623 · DOI · Paper page
  32. Tabrizi, 2018, The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials, Lipids Health Dis., 17, 123, 10.1186/s12944-018-0779-4 · DOI
  33. Buonomo, 2018, Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women, J. Ovarian Res., 11, 38, 10.1186/s13048-018-0411-2 · DOI · Paper page
  34. Roseff, 2020, Inositol treatment for PCOS should be science-based and not arbitrary, Int. J. Endocrinol., 2020, 6461254, 10.1155/2020/6461254 · DOI · Paper page
  35. Liu, 2013, Resveratrol protects against age-associated infertility in mice, Hum. Reprod., 28, 707, 10.1093/humrep/des437 · DOI · Paper page
  36. Zhang, 2016, SIRT1, 2, 3 protect mouse oocytes from postovulatory aging, Aging, 8, 685, 10.18632/aging.100911 · DOI · Paper page
  37. Cabello, 2015, Effects of resveratrol on ovarian response to controlled ovarian hyperstimulation in ob/ob mice, Fertil. Steril., 103, 570, 10.1016/j.fertnstert.2014.10.034 · DOI
  38. Ortega, 2015, Ovarian actions of resveratrol, Ann. N. Y. Acad. Sci., 1348, 86, 10.1111/nyas.12875 · DOI
  39. Aquino, 2014, Complementary therapy in polycystic ovary syndrome, Transl. Med. UniSa, 9, 56
  40. Ochiai, 2019, Preconception resveratrol intake against infertility: Friend or foe?, Reprod. Med. Biol., 19, 107, 10.1002/rmb2.12303 · DOI
  41. Kuroda, 2020, The actions of resveratrol in decidualizing endometrium: Acceleration or inhibition?, Biol. Reprod., 103, 1152, 10.1093/biolre/ioaa172 · DOI
  42. Ochiai, 2019, Influence of resveratrol supplementation on ivf–embryo transfer cycle outcome, Reprod. Biomed. Online, 39, 205, 10.1016/j.rbmo.2019.03.205 · DOI
  43. Ochiai, 2019, Resveratrol inhibits decidualization by accelerating downregulation of the CRABP2-RAR pathway in differentiating human endometrial stromal cells, Cell Death Dis., 10, 276, 10.1038/s41419-019-1511-7 · DOI
  44. Benrick, 2013, resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome, Evid. Based Complement Altern. Med., 2013, 964070, 10.1155/2013/964070 · DOI
  45. Manna, 2000, Resveratrol sup- presses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: Potential role of re- active oxygen intermediates and lipid peroxidation, J. Immunol., 164, 6509, 10.4049/jimmunol.164.12.6509 · DOI · Paper page
  46. Aggarwal, 2004, Suppression of the nuclear factor-κB activation pathway by spice-derived phytochemicals: Reasoning for seasoning, Ann. N. Y. Acad. Sci., 1030, 434, 10.1196/annals.1329.054 · DOI · Paper page
  47. Csaki, 2008, Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro, Biochem. Pharmacol., 75, 677, 10.1016/j.bcp.2007.09.014 · DOI · Paper page
  48. Shakibaei, 2007, Resveratrol in-hibits IL-1β–induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro, Ann. N. Y. Acad. Sci., 1095, 554, 10.1196/annals.1397.060 · DOI · Paper page
  49. Kiran, 2017, Flavonoid: A review on Naringenin, J. Pharmacol. Phytochem., 6, 2778
  50. Ho, 1998, Improved high-performance liquid chromatographic method for the analysis of Naringenin grapefruit juice without extraction, Pharm. Pharmacol. Commun., 4, 473
  51. Frabasile, 2017, The citrus flavanone naringenin impairs dengue virus replication in human cells, Sci. Rep., 7, 41864, 10.1038/srep41864 · DOI
  52. Kicinska, A., Kampa, R.P., Daniluk, J., Sek, A., Jarmuszkiewicz, W., Szewczyk, A., and Bednarczyk, P. (2020). Regulation of the mitochondrial bk ca channel by the citrus flavonoid naringenin as a potential means of preventing cell damage. Molecules, 25. · doi:10.3390/molecules25133010
  53. Wawrzkiewicz-Jałowiecka, A., Kowalczyk, K., Trybek, P., Jarosz, T., Radosz, P., Setlak, M., and Madej, P. (2020). In search of new therapeutics-molecular aspects of the PCOS pathophysiology: Genetics, hormones, metabolism and beyond. Int. J. Mol. Sci., 21. · DOI
  54. Hong, 2019, The flavanone, naringenin, modifies an-tioxidant and steroidogenic enzyme activity in a rat model of letrozole-induced poly-cystic ovary syndrome, Med. Sci. Monit., 25, 395, 10.12659/MSM.912341 · DOI
  55. Yuan, 2017, Rutin ameliorates obesity through brown fat activation, FASEB J., 31, 333, 10.1096/fj.201600459rr · DOI · Paper page
  56. Hu, 2017, Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat, J. Nutr. Biochem., 47, 21, 10.1016/j.jnutbio.2017.04.012 · DOI
  57. Olaniyan, 2019, Vitamin C suppresses ovarian pathophysiology in experimental polycystic ovarian syndrome, Pathophysiology, 26, 331, 10.1016/j.pathophys.2019.08.003 · DOI
  58. Bendich, 1986, The antioxidant role of vitamin C, Adv. Free Radic. Biol. Med., 2, 419, 10.1016/S8755-9668(86)80021-7 · DOI · Paper page
  59. Palamanda, 1993, Involvement of vitamin e and protein thiols in the inhibition of microsomal lipid peroxidation by glutathione, Lipids, 28, 427, 10.1007/BF02535941 · DOI
  60. Cicek, 2012, Vitamin E effect on controlled ovarian stimulation of unexplained infertile women, J. Assist. Reprod. Genet., 29, 325, 10.1007/s10815-012-9714-1 · DOI
  61. Izadi, 2019, Hormonal and metabolic effects of coenzyme q10 and/ or vitamin E in patients with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 104, 319
  62. Chen, J., Guo, Q., Pei, Y.H., Ren, Q.-L., Chi, L., Hu, R.K.H., and Tan, Y. (2020). Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: A retrospective cohort study. BMC Womens Health, 20. · DOI
  63. Monastra, 2018, Vitamin D: A steroid hormone with progesterone-like activity, Eur. Rev. Med. Pharmacol. Sci., 22, 2502
  64. Holick, 2007, Vitamin D deficiency, N. Engl. J. Med., 357, 266, 10.1056/NEJMra070553 · DOI · Paper page
  65. Li, 2011, Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome, Metabolism, 60, 1475, 10.1016/j.metabol.2011.03.002 · DOI · Paper page
  66. Wehr, 2009, Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome, Eur. J. Endocrinol., 161, 575, 10.1530/EJE-09-0432 · DOI · Paper page
  67. Snackey, 2013, The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: A systematic review, Eur. J. Endocrinol., 169, 853, 10.1530/EJE-13-0617 · DOI · Paper page
  68. Lerchbaum, 2012, Vitamin D and fertility: A systematic review, Eur. J. Endocrinol., 166, 765, 10.1530/EJE-11-0984 · DOI · Paper page
  69. Kadoura, 2019, Effect of calcium and vitamin d supplements as an adjuvant therapy to metformin on menstrual cycle abnormalities, hormonal profile, and IGF-1 system in polycystic ovary syndrome patients: A randomized, placebo-controlled clinical trial, Adv. Pharmacol. Sci., 2019, 9680390
  70. Miao, 2020, Effect of vitamin D supplementation on polycystic ovary syndrome: A meta-analysis, Exp. Ther. Med., 19, 2641
  71. Trummer, 2019, Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: A randomized-controlled trial, Eur. J. Nutr., 58, 2019, 10.1007/s00394-018-1760-8 · DOI · Paper page
  72. Lerchbaum, 2014, Vitamin D and female fertility, Curr. Opin. Obstet. Gynecol., 26, 145, 10.1097/GCO.0000000000000065 · DOI · Paper page
  73. Merhi, 2019, Crosstalk between advanced glycation end products and vitamin D: A compelling paradigm for the treatment of ovarian dysfunction in PCOS, Mol. Cell. Endocrinol., 479, 20, 10.1016/j.mce.2018.08.010 · DOI
  74. Merhi, 2018, Advanced glycation end products alter steroidogenic gene expression by granulosa cells: An effect partially reversible by vitamin D, Mol. Hum. Reprod., 24, 318, 10.1093/molehr/gay014 · DOI
  75. Forouhi, 2015, Effect of omega-3 fatty acids supplementation on testosterone levels in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials, J. Nutr. Sci. Diet., 1, 165
  76. Oner, 2013, Efficacy of omega-3 in the treatment of polycystic ovary syndrome, J. Obstet. Gynaecol., 33, 289, 10.3109/01443615.2012.751365 · DOI · Paper page
  77. Monk, 2014, n-3 polyunsaturated fatty acids and mechanisms to mitigate inflammatory paracrine signaling in obesity-associated breast cancer, Nutrients, 6, 4760, 10.3390/nu6114760 · DOI
  78. Calder, 2013, Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?, Br. J. Clin. Pharmacol., 75, 645, 10.1111/j.1365-2125.2012.04374.x · DOI · Paper page
  79. Poudyal, 2011, Omega-3 fatty acids and metabolic syndrome: Effects and emerging mechanisms of action, Prog. Lipid Res., 50, 372, 10.1016/j.plipres.2011.06.003 · DOI · Paper page
  80. Simopoulos, 2002, The importance of the ratio of omega-6/omega-3 essential fatty acids, Biomed. Pharmacother., 56, 365, 10.1016/S0753-3322(02)00253-6 · DOI · Paper page
  81. Martorell, 2018, Resolvins as proresolving inflammatory mediators in cardiovascular disease, Eur. J. Med. Chem., 153, 123, 10.1016/j.ejmech.2017.07.018 · DOI
  82. Sima, 2016, Therapeutic targets for management of periodontitis and diabetes, Curr. Pharm. Des., 22, 2216, 10.2174/1381612822666160216150338 · DOI
  83. Sadeghi, 2017, Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials, Diabetes Metab. Syndr., 11, 157, 10.1016/j.dsx.2016.06.025 · DOI
  84. Khani, 2017, Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome, J. Res. Med. Sci., 22, 64, 10.4103/jrms.JRMS_644_16 · DOI · Paper page
  85. Harris, 1990, The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man, Thromb. Res., 57, 517, 10.1016/0049-3848(90)90069-O · DOI
  86. Warstedt, 2009, The Effects of Omega-3 Fatty Acid Supplementation in Pregnancy on Maternal Eicosanoid, Cytokine, and Chemokine Secretion, Pediatric Res., 66, 212, 10.1203/PDR.0b013e3181aabd1c · DOI

Cited by

See all 98

Metadata

Authors
Iervolino, M., Lepore, E., Forte, G., Laganà, A. S., Buzzaccarini, G., & Unfer, V.
Venue
Nutrients
Publisher
MDPI AG
Published
2021-05-15
Volume
13
Issue
5
Pages
1677
ISSN
2072-6643 (ISSN-L)
OpenAlex
W3160583309
Cited by
98
References
15
FWCI
12.50
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review. https://app.cochat.ai/papers/10.3390/nu13051677
The paper
Iervolino, M., Lepore, E., Forte, G., Laganà, A. S., Buzzaccarini, G., & Unfer, V. (2021). Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review. Nutrients. https://doi.org/10.3390/nu13051677

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.